Drug resistance tuberculosis
challenging health concern in resource limited countries (DRC)
Marie José Kabedi Bajani, Specialist in Medical Biology, Option Microbiology at the Department of Medical Biology of University Clinics of Kinshasa. Head of the Mycobacteria Unit at the Microbiology Department, Head of Work and Doctoral Student at the Faculty of Medicine of the University of Kinshasa (DRC).
Multidrug-Resistant Tuberculosis is a Major Public Health Problem Around the World, Despite Strategies (DOTS, DOTS PLUS and Stop TB) set up to fight this scourge, MDR-TB is still a real threat to Global Health Programs. The situation is particularly serious in developing countries, which account for nearly 95% of detected cases. The emergence of MDR-TB strains could jeopardize the success of TB eradication programs. Given the limitations of diagnostic and follow-up
tests for patients undergoing treatment in resource-poor countries (DRC), we evaluated two tests: the bladder susceptibility test that detects resistance to rifampicin, Kanamycin and Ofloxacin and the Fluorescein diacetate staining technique, which makes it possible to reveal only viable bacilli. Slide susceptibility was able to determine within 10 days the level of rifampicin resistance (47.3%), Ofloxacin (15.7%) and Kanamycin (16.7%) in whole population.